Promising Phase III data for a new passive vaccine against RSV
May 10, 2021Infection by Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in infants. The currently available preventive treatment is a monthly injection with an anti-RSV antibody, which is only given to high-risk infants and only temporarily provides protection due to a limited half-life. Now, a new antibody against RSV, which was developed by scientists of Amsterdam UMC
spin-off AIMM Therapeutics, has come one step closer to market authorization, showing positive results in a Phase III clinical trial performed by pharma companies Astra Zeneca and Sanofi. This antibody, being more stable than the existing antibody, will only need to be administered once per RSV-season and should become available to all infants.
For more information click here.
Photo credit: Respiratory syncytial virus (RSV) infection – Case 288 by Yale Rosen. Photo is cropped.
More news
NWO Take-off Approvals Announced for VU and UvA
The fall 2024 round of the NWO Take-off Grant has brought exciting news for Amsterdam’s academic community. Four innovative projects have been selected, with two from the Vrije Universiteit Amsterdam (VU) and two from the Universiteit van Amsterdam (UvA). The Take-off grant empowers academics to explore the feasibility and commercial potential of their science-based ideas, […]
News
UvA spin-off Eddytec wins Women TechEU Grant
This €75k funding will help validate their business model and accelerate their go-to-market strategy. Eddytec’s technology aims to revolutionize maintenance and quality control processes for aircraft components, making them faster, easier, and more cost-effective.
News
Highly impactful Amsterdam stroke innovation now reaches even more patients
Ten years ago, a groundbreaking medical innovation made it possible to remove a blood clot from stroke patients using a catheter procedure. The health benefits for patients after this procedure are often much greater than with other treatments. Thanks to the collaboration with Amsterdam UMC, this treatment is now also being performed at the Noordwest Ziekenhuisgroep in Alkmaar.
News